Our studies indicate that LY6D distinguishes between mouse and human skin BCC- and SCC-like states, raising the possibility that it serves as a general diagnosis and treatment biomarker for other basosquamous cancers. This evidence concerns the gene LY6D and skin basal cell carcinoma.